arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ELI LILLY & Co

LLY
$1191.45 ▲ +26.26 (+2.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
74 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

ELI LILLY & Co demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $1.1T
Dividend Yield
Revenue Growth 55.5%
Op. Margin
ROIC
FCF / Share $5.96
Trailing P/E 144.1x
Price / Book 34.2x
FCF Yield 0.5%
Debt / Equity 1.26
info Valuation on last close. End-of-day price, Aug 6, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.80B
↑ +55.5%
Net Income Profit after all expenses
$7.40B
↑ +168.0%
FCF / Share Free cash flow per share
$5.96
↑ +221.7%
Long-Term Debt Long-term obligations
$39.37B
↓ -3.7%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
91
Returns
99
Financial Health
17
Cash Quality
55

Dividend History

Dividend / share · sourced from SEC filings
$6.23 Latest / share
+15.4% YoY
+14.4% 9-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters